NEW YORK, July 2 /PRNewswire-FirstCall/ -- China Aoxing Pharmaceutical Company, Inc. , a China-based pharmaceutical company specializing in analgesics and pain management products, including Oxycodone, Pholcodine, Naloxone, and Tilidine, announced today the election of Mr. Jiaqi Wang to its Board of Directors. Mr. Wang replaces Mr. Zhongshun Qiao, who resigned from the Board for personal reasons.
Mr. Wang, 44, is the founder and president of Hebei Jinzita Investment Company, Ltd, an investment firm focusing on corporate finance, mergers & acquisitions in China. Mr. Wang spent most of his career time in Bank of China (“BOC”). From 1984-2004, Mr. Wang worked for BOC in several different functions, ranking from Client Manager to Vice President of Shijiazhuang Branch of BOC. He also spent three years at the Hong Kong office of the BOC overseeing currency trade, international finance and accounting transactions of the audit department. During his twenty-year tenure at the BOC, he was in charge of many investment projects across various industry sectors and gained extensive experience in directing strategic planning, business execution and risk management for Chinese corporations.
Mr. Wang has a B.A. in Finance from Hebei University of Economics & Business and an associate degree in international finance from the Bank of China Community College. He has also received an auditing certificate from the Bank of China and a mid-level certificate in accounting from the London Chamber of Commerce and Industry (LCCI).
Zhenjiang Yue, China Aoxing’s Chairman and CEO commented, “We are pleased to have Mr. Wang join our Board. He brings extensive experience in corporate management, finance and accounting which will be extremely beneficial to our company as we assess strategic issues and capitalize on opportunities to broaden our presence for high value pain management products in China.”
Mr. Yue continued, “I would like to thank Mr. Qiao for his dedication and service to our company, we respect his decision and wish him well in his future endeavors.”
About China Aoxing Pharmaceutical Group
China Aoxing Pharmaceutical Company, Inc. is a pharmaceutical company in China which specializes in research, development, manufacturing and distribution of a variety of analgesics and pain management products. Its operating subsidiary, Hebei Aoxing Pharmaceutical Group Co. Ltd, is a corporation organized under the laws of the People’s Republic of China. Hebei Aoxing is one of only a handful of companies in China to be granted the license to manufacture certain drugs including Oxycodone, Pholcodine, Naloxone, Tilidine, and is working closely with the Chinese government to assure availability throughout China.
Contact Dr. Hui Shao Senior Vice President China Aoxing Pharmaceutical 201-420-1075 Ashley Ammon MacFarlane & Bill Zima Integrated Corporate Relations, Inc. 203 682 8200
China Aoxing Pharmaceutical Company
CONTACT: Dr. Hui Shao, Senior Vice President, China Aoxing Pharmaceutical,+1-201-420-1075; Ashley Ammon MacFarlane & Bill Zima, Integrated CorporateRelations, Inc., +1-203-682-8200
Web site: http://www.aoxingyaoye.com//
